Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins - Takeaways - MDSpire

Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins

  • By

  • Vikrama Raja

  • Carlos Aguiar

  • Nasreen Alsayed

  • Yogeyaa S. Chibber

  • Hussein ElBadawi

  • Michel Farnier

  • Kumari Pushpa

  • Lale Tokgözoglu

  • Alberto Zambon

  • Jean-Pascal Berrou

  • Michel P. Hermans

  • June 4, 2026

  • 0 min

Share

  • 1

    Dyslipidemia management traditionally focuses on lowering LDL-C, yet residual cardiovascular risk persists despite optimal control of traditional risk factors.

  • 2

    Remnant cholesterol (RC), derived from triglyceride-rich lipoproteins, is identified as a significant contributor to residual cardiovascular risk.

  • 3

    Fenofibrate, when combined with statins, effectively reduces non-HDL-C levels and may help address RC-related cardiovascular risk.

  • 4

    The combination of statin and fenofibrate therapy shows superior efficacy in lowering non-HDL-C compared to other TRL-lowering strategies.

  • 5

    Long-term studies support the safety and tolerability of fenofibrate, reinforcing its role as an adjunct therapy in dyslipidemia management.

Original Source(s)

Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins

  • by Vikrama Raja, Carlos Aguiar, Nasreen Alsayed, Yogeyaa S. Chibber, Hussein ElBadawi, Michel Farnier, Kumari Pushpa, Lale Tokgözoglu, Alberto Zambon, Jean-Pascal Berrou, Michel P. Hermans

  • June 4, 2026

Related Content

Wearables May Boost T2D Mobility

Outpatient intervention combined physiotherapist counseling with wrist-worn activity monitoring.

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis

Correlation between cardiorespiratory fitness and body composition in individuals with different glucose metabolism statuses